Understanding of Pathomechanisms and Clinical Practice for Vitiligo

Vitiligo is an acquired depigmentation disease that affect approximately 0.5% to 1% of the population1. There are no sex differences in terms of the onset thereof, and it is said to potentially occur in any age group2. Vitiligo is broadly classified into non-segmental vitiligo, which occurs clinically independent of innervation areas and often fluctuates in a disease course, segmental vitiligo, in which lesions are observed along dermatomes, and mixed vitiligo, which combines both types. While non-segmental vitiligo often occurs in young people between the ages of 10 and 30 years, the onset of segmental vitiligo is commonly even younger than that of non-segmental vitiligo3. One of the onset mechanisms of non-segmental vitiligo is thought to involve dysregulation of autoimmune responses. As for complications, 20.3% of non-segmental vitiligo patients are associated with autoimmune disease, with thyroid disease and 12% with alopecia areata at 5.3%4, furthermore, familial aggregation is presented in 20% to 30% of vitiligo patients5. Vitiligo in prepubertal children is more likely to be accompanied by Koebner's phenomenon than in those with its onset after puberty. There are many cases of prepubertal children with a tendency toward spontaneous regression, and a high proportion of cases with a family history of vitiligo6. Interestingly, recent reports indicate that the age of onset of vitiligo has increased between 1970 and 2004, with a biphasic onset peak in adult vitiligo7. It has been noted that spouses of patients with vitiligo have a 1.89- to 1.96-fold higher risk of developing vitiligo8; therefore, in addition to genetic background factors, the influence of living environment factors may be involved in the development of modern vitiligo9.

Here, I provide current knowledge about the pathogenesis of and commonly used treatments for vitiligo and propose the factors needed for optimal and precision medicine in vitiligo patients.

Vitiligo is a representative acquired hypopigmented disorder in which melanocytes decrease in number or disappear due to complicated pathogenic influences. Although the pathophysiology has not been completely elucidated, recent studies have clarified it in both mouse and human settings. Mainly in non-segmental vitiligo, based on the genetic background including genes alteration, i.e., single nucleotide polymorphisms, related to melanocyte fate and HLAs haplotype10 in addition to environmental factors like dysbiosis and a high fat/salt diet triggering proinflammatory conditions9, the following compound steps are involved in the vitiligo pathogenesis: 1) damage to melanocytes due to oxidative stress, such as reactive oxygen generated in the process of melanin synthesis; 2) decreased function of melanocytes or melanocyte stem cells; 3) cytotoxic autoimmune responses to melanocytes; and 4) melanocytes in vitiligo patients being inherently vulnerable to oxidative stress. In association with these processes, melanocytes and/or melanocyte stem cells eventually disappear as a complication of these processes and vitiligo lesions are expanded or maintained without repigmentation. Fig. 1 is a schema depicting the relationship between the currently proposed pathogenic factors in vitiligo. It is thought that not only apoptosis but also various mechanisms, such as necrosis, necroptosis, pyroptosis, and apoptosis, are involved in the disappearance of vitiligo melanocytes11. Pyroptosis is a cell death pattern with gasdermin D and caspases activation which are stimulated by such factors as damage-associated molecular patterns (DAMPs)12 and it is also partly induced by cytotoxic lymphocytes through granzyme-A-cleaved gasdemin B13. Oxeiptosis is a reactive oxygen species (ROS)-sensitive, caspase independent, non-inflammatory type of cell death triggered by viral pathogens14. Various types of insufficient cellular behavior in vitiligo melanocytes have been proposed to induce the accumulation of oxidative stress. Abnormalities in the autophagy system, in which the inactivation of ATG5 and 12 are considered to be representative examples, lead to susceptibility to oxidative stress15. In addition, the downregulation of Kelch-like ECH associated protein 1 (Keap 1)-NF-E2 related factor 2 (Nrf 2) pathway and an impaired enzymatic ratio between reduced glutathione (GSH) and oxidized disulfide (GSSG) results in an accumulation of oxidative stress15. Alternatively, adhesion factors such as decreased E-cadherin, vitiligo melanocytes leaving the basal layer, and cell membrane abnormalities can also cause melanocyte loss16. Increased oxidative stress not only damages melanocytes, but also induces autoimmunity through the upregulation of the calreticulin expression and translocation to the cell membrane17. On the other hand, it has recently become clear that CD49a⁺CD103⁺CD8⁺ resident memory T cells reside in vitiligo lesions, and they provide pathologic adaptive immunity against melanocytes by producing interferon-gamma (IFN-γ) in addition to perforin and granzyme B when stimulated with interleukin (IL)-15 from keratinocytes18, 19. In addition to keratinocytes, IFN-γ signaling from anatomically distinct dermal fibroblasts notably activates the cytotoxicity of CD8 T cells20. These findings indicate that skin resident cells including keratinocytes and dermal fibroblasts may play a key role in regulating the microenvironment of vitiligo immunity. Moreover, CD8⁺ resident memory T cells expressing CXCR3 imprinted in vitiligo lesions are reported to act as disease flares even in cases with stable disease21. Aside from T cells, Dendritic cells recognizing melanocyte antigens and IL-6/8 released from stressed melanocytes can activate memory T cells22. Type-1 innate lymphoid cells of NK and innate lymphoid cell (ILC) 1 induce the apoptosis of melanocyte expressing CXCR3B under IFN-γ production, thereby initiating the subsequent adaptive T-cell autoreactivity23. These auto-immunogenic factors pathologically interact with the quiescent and/or active vitiligo skin. Correctly understanding the mechanisms for ROS accumulation and the associated types of unique autoimmunity is expected to lead to the proper clinical management of vitiligo.

Fig. 1
Current understanding of vitiligo pathomechanisms. SNPs: single nucleotide polymorphisms, GSH: reduced glutathione, GSGG: oxidized disulfide, IL: interleukin, IFN-γ: interferon-gamma, ILC1: innate lymphoid cell 1, Keap 1: Kelch-like ECH associated protein 1, Nrf 2: NF-E2 related factor 2.

• Click for larger image
• Download as PowerPoint slide

To refine daily clinical practice for vitiligo patients, the following eight items should be considered. 1) There are segmental and non-segmental disease types with different treatment methods and clinical courses. Segmental type is likely to be indicated for surgical treatment. 2) Regarding age, vitiligo in children has characteristics such as a high possibility of spontaneous remission, high response to treatment, and restrictions on ultraviolet (UV) treatment6. 3) Following detailed interviews and a search of the patient's history of treatment, duration of illness, and presence or absence of related diseases, it was found that, despite individual differences, the shorter the duration of illness, the more melanocytes or progenitor cells remain, and the easier it is to regenerate pigment. 4) Vitiligo Area Scoring Index, VETFa (Vitiligo European Task Force assessment), and VES (Vitiligo Extent Score) methods have been proposed to quantify the spread and area of lesions24, clinicians can conduct measures using an appropriate and convenient method. Moreover, https://www.vitiligo-calculator.com allows us to automatically calculate the VSAS (Vitiligo Signs of Activity Score), which is an index for quantifying activity in addition to the VES. 5) It is also important to ask questions regarding the patient's desired site for treatment and to understand the therapeutic response depending on the site. The face and neck regions react more easily, while the extremities and mucosal surface react less25. 6) To understand disease activity, observe the VIDA (vitiligo disease activity) scoring and the presence or absence of activity signs such as confetti-like, Koebner, and trichromatic lesions26. Especially, when the confetti sign is present, activity is high, and Koebner’s phenomenon is likely to occur in pediatric patients. The dermoscopic view is also useful, with satellite and “tapioca sago” findings also indicating high activity27. 7) Whether melanocytes and/or melanocyte progenitor cells remain in vitiligo lesions is important for predicting pigment regeneration. Pure white lesions with white hair or no residual pigment on Wood's light may indicate poor repigmentation28. 8) The repigmentation pattern should be considered to achieve cosmetic treatment. As mentioned above, vitiligo is affected by a wide variety of clinical factors in achieving cosmetic treatment; therefore, it is important to accurately evaluate each case and lesion and practice individualized and optimal precision medicine.

Since 1996, guidelines for the treatment of vitiligo have been proposed, mainly in Europe and the United States29, 30, 31, 32, 33. There are four main strategies for the treatment of vitiligo: topical therapy, UV therapy, systemic immunoregulation using steroids, and surgical treatment. Comparing the treatments recommended by the major guidelines currently published as shown in Table 1, calcineurin inhibitors (two types: tacrolimus and pimecrolimus) are known to be very effective for repigmentation, and are commonly used as well as topical steroids. Topical vitamin D3 is not recommended in the UK and European guidelines because of its controversial efficacy. For systemic therapy, oral steroids are recommended for advanced cases, with no changes for 12 months, as the guideline for surgical treatment. Cellular grafting, such as cultured or noncultured epidermal single cells (NCES) containing melanocytes and noncultured outer root sheath cells (NCORS) as regenerative therapy, has been actively performed to cover the wider lesions and to improve repigmentation34. The mean repigmentation score was significantly higher in NCES compared to NCORS. A meta-analysis of 117 studies in comparison to several types of tissue and cellular grafting demonstrated that the treatment efficacy was associated with age, the anatomic site. and the subtype of vitiligo35.

Table 1
Comparison of published treatment guidelines

• Click for larger image
• Click for full table
• Download as Excel file

Comparing the history of phototherapy, while oral and topical psoralen UVA had been mainstream in 1996 in the United States, the number of irradiations was described in the United Kingdom in 2008, with the narrow-band set at an upper limit of 200 times for Fitzpatrick skin types I~III. In the European guidelines of 2013, the narrow-band was selected as the first choice for the non-segmental type, with excimer light/laser indicated for localized lesions. Currently, target-type narrow-band UVB devices have been developed, and devices for home irradiation are becoming widespread. The European guidelines state the efficacy of phototherapy should be verified every 3 to 6 months for up to 2 years. The combined use of topical steroids or calcineurin inhibitors can improve repigmenration efficacy. According to the Japanese guidelines, the maximum duration of phototherapy was recommended to set at 6 months or 60 times for those aged 16 years and older, and the combined use of topical vitamin D3 is also expected based on positive data obtained from a systemic review and meta-analysis36. However, the repigmentation effect obtained by the administration of additional topical vitamin D3 still remains inconclusive36, 37. According to a proposal by the 2017 Vitiligo Working Group, phototherapy can be performed 2 to 3 times a week from around the age of 7~10 years, with no upper limit on the number of times for skin types IV~VI, which includes most Asian patients. In this manner, the types of phototherapies have gradually upgraded, with irradiation methods being described in greater detail year by year as treatment evidence has accumulated (Table 2).

Table 2
Comparison of phototherapy among guidelines

• Click for larger image
• Click for full table
• Download as Excel file

The advantages and disadvantages of the treatment methods described in the guidelines are summarized in Table 3. Combination therapy, in which topical therapy, UV therapy, and surgical therapy are combined, is expected to improve therapeutic response when appropriately combined. The combination of topical tacrolimus and mometasone was superior to topical tacrolimus alone45. In a randomized controlled trial on the combination therapy of topical calcipotriol and topical betamethasone dipropionate and monotherapy, the combination group exhibited early therapeutic effects and reduced the frequency of recurrence and side effects after pigmentation46. Combination therapy with topical steroids and narrow-band UVB or 308 nm excimer laser/light has been reported to be more effective than either treatment alone47, 48. In recent years, there has been a high level of evidence regarding the combined use of topical calcineurin inhibitors, such as tacrolimus ointment and pimecrolimus ointment, and UV light therapy to vitiligo49, 50. With respect to the safety of topical calcineurin inhibitors, immunosuppression does not increase the risk of serious infections or development of malignant tumors, including malignant lymphoma51. While there are a small number of meta-analyses on the combined use of topically activated vitamin D3 and UV therapy, which is reported to be more effective than UV therapy alone36, some reports indicated that it was not significantly more effective than narrow-band UVB monotherapy52. The combined use of UV following surgery has been reported to promote pigment regeneration, although not at the level of a randomized controlled trial, so it is desirable to start UV therapy preferably 3 to 4 weeks following surgery53, 54. Furthermore, a systematic review reported that erbium YAG lasers, fractional lasers, topical 5-FU, intramuscular injection of betamethasone, etc., improved the repigmentation effect as a combination therapy with narrow-band UVB55. As mentioned above, many reports indicate that combination therapy with phototherapy is more effective. Once UV light therapy has reached a plateau in terms of repigmentation, then the above-described additional treatments are expected to improve efficacy.

Table 3
Characteristics of each treatment

• Click for larger image
• Click for full table
• Download as Excel file

Recent studies have shown that the local immune environment generated by vitiligo lesions plays an important role in the onset and maintenance of vitiligo. IFN-γ-signals activate the intracellular JAK-signal transducer and activator (STAT) 1 pathway to produce CXCL9/10 in keratinocytes, after which cytotoxic T cells expressing the receptor CXCR3 migrate to the epidermis and release molecules, such as granzyme B and perforin, to attack melanocytes. Furthermore, the mechanism by which IFN-γ reactivates keratinocytes has been clarified; therefore, JAK-targeted therapeutic applications have come to be used for the pathology of the “IFN-γ-JAK-STAT1” axis56, 57. Clinical trials for vitiligo with JAK inhibitors have been conducted and positive outcomes have been observed worldwide. For example, when the JAK inhibitor tofacitinib was used in 10 patients with vitiligo, regrowth of pigment occurred in 5 patients, with the effect being particularly high when used in combination with UV light58. Another study used the topical JAK inhibitor ruxolitinib cream in 157 patients with vitiligo and reported a significant increase in the rate of achieving 50% repigmentation of facial lesions after 24 weeks of using the cream with the highest concentration of 1.5%59. In addition to the ongoing clinical trials of JAKs/TYKs and related molecular inhibitors reviewed in reference60, the development of therapeutic drugs targeting cell membrane molecules and cytokines involved in vitiligo immunity is progressing rapidly.

Currently, new vitiligo treatment candidates, such as JAKs inhibitors, have appeared, and the pathology of vitiligo has been dissolved at an accelerated pace. Going forward, it is required that the updated guidelines will be formulated to incorporate new findings and meet the needs of the times with a global consensus. Clinicians and carers need to aim for an optimal individual vitiligo treatment, that is “precision vitiligo medicine,” by accurately understanding the substance of each case and each lesion.